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Abstract: Calmodulin plays a role in several life processes, its flexibility allows binding of a number of different ligands from 
small molecules to amphiphilic peptide helices and proteins. Through the diversity of its functions, it is quite difficult to find new 
drugs, which bind to calmodulin as a target. We present available structural information on the protein, obtained by X-ray 
diffraction, nuclear magnetic resonance spectroscopy and molecular modeling and try to derive some conclusions on structure-
activity relationships. 
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INTRODUCTION 
 Calmodulin (CaM) is the primary Ca2+ signaling protein in eukaryotic biology. It is ubiquitous and 100% 
conserved among vertebrates [1, 2]. Higher eukaryotes, including humans, possess three distinct bona fide CaM 
genes differentially regulated, encoding the identical protein [3, 4]. CaM is a small, 148 amino acid protein and is 
highly acidic, with a pI of approximately 4.6 [5].  The structure of CaM consists of homologous N-and C-terminal 
domains linked together by a flexible tether, usually referred to as the “central linker” [6]. Within each terminal 
lobes, there are two Ca2+-binding "EF-hand" motifs flanked by tightly structured domains [7]. Upon binding Ca2+ 
ions, extensive hydrophobic surfaces become exposed to the solvent, promoting the interaction of CaM with target 
proteins. The flexibility of the CaM molecule facilitates its binding to diverse array of targets, including more than 
100 proteins important for Ca2+-dependent intracellular signaling. CaM is the mediator of such diverse biological 
processes as muscle contraction, fertilization, cell proliferation, vesicular fusion, and apoptosis [8]. Because of its 
involvement in so many vital processes, deletion of the CaM gene is lethal [9]. One of the few unifying 
characteristics of the CaM binding sequences is the ability of all to form basic, amphiphilic helices when complexed 
with CaM [10]. 
 Small, hydrophobic molecules also bind to CaM and modify its function by inhibiting, or modifying the 
interaction with other proteins [11-18]. Some of these compounds used as pharmacological agents to block CaM-
mediated enzyme activation may act as antipsychotics, muscle relaxants, antidepressants, minor tranquilizers, and 
local anesthetics [19, 20]. CaM antagonists (such as trifluoperazine [TFP] and many others) are also being evaluated 
for the treatment of cancers that are both sensitive and resistant to conventional anticancer drugs [21-23]. 
 In Ca2+-free, or apo-CaM, the structure of both terminal domains is defined by two helix-loop-helix motifs 
called EF-hands, connected by short, slightly distorted beta sheets.  Although the two domains share 46% sequence 
identity and highly similar globular folds in the absence of Ca2+, the C-terminal lobe is in dynamic equilibrium 
between its closed and semi-open conformation while the N-terminal domain remains closed [24, 25]. This means 
that the hydrophobic amino acids of the domains are shielded from the solvent.  The central linker of the protein 
(residues 65 – 92) is extremely flexible in solution, especially near its midpoint, resulting in the two domains 
tumbling independently of one-another [6, 26-28] (see Fig. (1)).  
 
Fig. (1).   Restructuring of calmodulin in response to Ca2+-binding.  A., B. Two forms of the solution structure of Ca2+-free CaM. 
(pdb code: 1dmo [27]) C. Crystal structure of the Ca2+-loaded form (pdb code: 1cll [29]).  Homologous N- and C-terminal regions 
are colored black, the central linker is gray. Ca2+ ions are shown as dark grey spheres. 
 
 Ca2+-binding by ligand-free CaM takes place in sequential steps, first to the C- and then to the N-lobe.  Ca2+ 
binding causes a change in the overall shape of the molecule from a globular ellipsoid to a dumbbell shape, and 
induces characteristic changes within the terminal domains too.  The two terminal domains rotate outward and their 
separation increases.  The central linker remains highly flexible in solution [6] while forms a helix in the crystal 
structure [29] (see Fig. (1)).  The solution structures reflect a more compact overall shape, with smaller radius of 
gyration [30, 31].  Molecular dynamics studies also indicate that the central linker is unlikely to form a helical 
structure in solution, and behaves like a flexible tether connecting the terminal lobes [32, 33].  The domains rigidify 
upon Ca2+ binding and the helix pairs of the EF-motifs reorient with respect to each other.  This causes a significant 
change, opening deep hydrophobic patches within the lobes (see Fig. (2)). This highly active conformation of the 
lobes is correspondingly referred to as their open conformation.  The domains retain their previous diversity, the N-
domain was shown to be considerably less open under Ca2+-ligating conditions too [34].  The hydrophobic patches of 
CaM are surrounded by negatively charged amino acids, therefore the Ca2+-activated state attracts ligands of 
hydrophobic and/or positively polarized nature. 
 
Fig. (2). Distribution of polar (dark gray) and hydrophobic (light gray) amino acids of the Ca2+-loaded form of CaM (pdb code: 
1cll [29]) in two, 90° rotated, views.  N- and C-terminal lobes are shown at the top and the bottom, respectively, showing the 
extended, hydrophobic surfaces of the “open” form. 
 
 CaM contains Met side chains in unusually high abundance, accounting for nearly half of the hydrophobic 
surface of each patch [11]. These methionines were shown to become solvent exposed in the open conformation of 
CaM [35, 36], and are essential for CaM’s ability to accommodate such different ligands [37, 38] (see Fig. (3)).  Met 
side chains are highly pliable [36, 39], and they are ideal for creating favorable van der Waals interactions due to the 
polarizability of sulfur and are at the same time fairly compatible with the surrounding aqueous medium [38, 40]. 
Ca2+-CaM is therefore equipped with flexible, dynamic and highly attractive hydrophobic binding surfaces on each 
lobe [5]. 
 
Fig. (3).   Localization of methionine side chains at the entrance of the hydrophobic patches in the Ca2+-loaded form of CaM (pdb 
code: 1cll [29]) 
 
CALMODULIN AND ITS TARGETS 
 
 A number of different mechanisms of how CaM activates its target proteins have been described [1].  
“Auto-inhibitory domain activation” is a process where CaM binding displaces the substrate-imitating auto-
inhibitory domain of the protein from the active site by wrapping around it and diminishing its contacts with the 
catalytic region.  In these complexes the overall structure of CaM is globular, the central linker is significantly bent. 
In most cases the protein recognizes sequence motifs classified as the 1-10, 1-14 or 1-16 motif which stand for the 
target carrying two, preferentially bulky residues separated by 8 or 12 or 14 amino acid residues, and their subsets, 
such as the 1-5-10 or the 1-8-14, and 1-5-8-14 motif, where three or more hydrophobic residues define the binding 
sequence. [41].  CaM dependent Ser/Thr kinases such as CaM kinase I/II/IV, CaM kinase kinase, myosin light chain 
kinase, as well as cerebral nitric oxide synthase, plasma membrane Ca2+ pumps and the N-methyl-D-aspartate 
(NMDA) receptor belong to this group. Based on the comparison of 17 such compact structures the concept of 
FLMM cavities was derived, where the letters stand for the one letter codes of  Phe19, Leu32, Met51, Met71 of the 
N-terminal hydrophobic patch, and Phe92, Leu105, Met124, Met144 of that of the C-terminal domain [42].  These 
hydrophobic patches typically accommodate Phe, Trp or Tyr residues of the target, although the less specific N-
terminal FLMMN shows greater variability (see Fig. (4)). Antagonist binding can also be described in terms of 
FLMM binding pockets, 
 
Fig. (4).  The “wrap-around” conformation of bent CaM-target complexes. (A) NMDA receptor - CaM complex (pdb code: 2hqw, 
[42] ), bound Phe residue, (B) myosin light chain kinase - CaM complex (pdb code: 2bbm, [101] ), bound Trp residue trapped by 
the C-terminal FLMM pocket. 
 
since trifluoroperazin, the most studied inhibitor of CaM (see below), binds to both FLMM cavities.  From the 
crystal structures of complexes belonging to this group the following CaM residues can be seen in close contact 
(nonhydrogen atoms within 3.5 Ǻ) with target sequences:  one or two of the three acidic residues of the N terminal 
sequence Glu7/Glu11/Glu14, Glu84 or Glu87 of the central linker, Glu114 or Glu127 of the C-terminal domain, 
along with one or two of the terminal methionines Met124/Met144/ Met145.   
 Calcineurin is a Ser/Thr protein phosphatase which binds to a very similar binding site of CaM as described 
above, but achieves it using a strikingly different architecture. In a 2:2 complex, CaM displays a native-like extended 
conformation while the calcineurin binding sequence is in alpha-helical conformation. However, the N-terminal lobe 
from one CaM and the C-terminal lobe from another form a combined binding site to trap the peptide, in a unique X-
shaped arrangement [43, 44]. The binding sites thus created are quite similar to that of the most commonly seen bent 
complexes. Hydrophobic interaction between Val and Phe residues of the calcineurin segments and Met73 and 
Met77 of the neighboring CaM molecules rigidify their central helices, while a unique “electrostatic-knot” is bound 
by Arg residues from both calcineurins and Asp81 and Glu84 of CaM (see Fig. (5)). These interactions are sufficient 
to stabilize the 2:2 complex in solution, too.  This finding was reaffirmed in a molecular dynamics study, where it 
was shown that this surprising arrangement is stabilized by the ligand, and disassembles in absence of it [45].  Close 
contacting CaM residues in the calcineurin complexes are: Glu11/Glu14, Met72, Met 73, Met77, Asp81, Glu84, and 
Met144/Met145. 
 
Fig. (5).  The unique X-shaped arrangement of the calcineurin - CaM complex, showing explicitly the cluster of polar amino-acids 
(in ball-and-stick representation) forming the ionic lock of this unusual arrangement. 
 
 Following an alternative activating mechanism the disordered substrate binding site of the target protein is 
actually assembled by its complexation with CaM – residues previously solvent exposed are brought into proximity 
while CaM itself is engulfed by the protein in an extended conformation. Bacillus anthracis anthrax adenyl cyclase 
exotoxin behaves accordingly [46].  A strong, nanomolar scale interaction is formed between the edema factor of the 
toxin and CaM.  Analyzing the different crystal structures available describing this complex [47-50], the consensus 
set of CaM residues forming the interaction are both acidic amino acids and members of the terminal hydrophobic 
patches: Glu11, Glu14, Phe19, Ser38, Glu87, Arg90, Lys94, His107, Leu112, Glu114, Met124, Asp131, Met145.  
The binding event itself appears to be a multi-step process, mediated by electrostatic interaction of the positive 
charge of a Lys that is exposed in the CaM-free state of the toxin which forms a favorable electrostatic interaction 
with the negative charge of CaM.  Interestingly, the CaM-binding sequence of the edema factor contains a 1-8-14 
motif, but these residues do not interact with CaM, showing how difficult it is to pinpoint CaM binding sequences or 
to predict the type of interaction between CaM and its targets in absence of structural information.   
 Another adenyl cyclase toxin from Bordatella pertussis, the etiologic agent of whooping cough, was also 
co-crystallized with the C-teminal domain of CaM, where a very similar set of CaM residues coordinated it [51].  
However, in case of the anthrax toxin a Leu, while in the complex formed with the Bordatella pertussis toxin, a Trp 
residue is hosted by the C-terminal characteristic hydrophobic pocket. Molecular dynamics simulations of the full-
length CaM- Bordatella pertussis toxin complex supported by mutagenesis and functional studies revealed that the 
toxin interacts with the N-terminal Ca2+-binding domains of CaM differently from anthrax edema factor, in spite of 
their high structural similarity [52].   
 Apo-CaM (Ca2+-free CaM) can also complex a number of targets.  The CaM binding region of these 
proteins usually contains an IQ motif. This motif consists of the IQXXXRGXXXR sequence or some close variant of 
it, which appears once or in tandem within the target sequence [41]. Unconventional myosin V forms such a complex 
in absence of Ca2+ in folded, inactive conformation, where all six of its IQ motifs bind the extended apo-CaM.  The 
crystal structure with one IQ peptide bound to the C-terminal domain of apo-CaM shows the peptide bound by a 
shallow hydrophobic groove lined by Phe92, Leu105, Met124, Ala128, Phe141 and Met144. A similar set of 
residues forms the deep hydrophobic pocket in Ca2+-loaded CaM, but the orientation of the F and G helices is 
different in the semi open conformation of the Ca2+-free state.  Other CaM residues participating in the interaction 
are Glu11, Glu14, Asn42, Met109, Lys115, Glu123, and Glu127. This conformation cannot bind Ca2+ tightly, since 
the chelating residues are misoriented, which has implications for the activity of the enzyme. At low Ca2+ 
concentration a transformation to the unfolded, active state takes place, while high Ca2+ concentrations cause 
inactivity due to CaM dissociating from one or more of the IQ motifs [53].  A similar effect can be seen in the case 
of CaM interacting with voltage gated calcium channel CaV1.2.  In the initial phase of the interaction apoCaM binds 
to the IQ motif of the CaM binding region.  This association is necessary for the rapid binding of Ca2+ to C-terminal 
CaM, which in turn results in the release of IQ.  Following this the C-lobe engages another region, resulting in the 
Ca2+-dependent inactivation of the channel [54].   
 CaM is also a modulator of caldesmon, a regulator of smooth muscle contractions.  Most likely, CaM binds 
to caldesmon in an extended conformation [55].  The Trp residues of caldesmon play key role in the association. 
Mutagenesis and fluorescence titration results suggest a great degree of flexibility in the interaction. Native binding 
can be disrupted and alternative spatial arrangements achieved [56]. 
 CaM, in complex with the binding domain peptide of HIV-1 matrix protein p17 also forms an extended 
structure.  The peculiarity of this complex is that it is stabilized by electrostatic interactions instead of the 
hydrophobic complementary seen in most CaM-target complexes.  Glu47, Asp50, Asp56 of the N-terminal, Glu139 
of the C-terminal domain participate in ligation, but most significantly Glu67, Arg74, Asp78, and Glu82 of the 
flexible linker between the two [57].  
 A 2:2 tetramer complex is formed between two molecules of rat Ca2+ activated K+ channel and the 
constitutively bound two molecules of CaM. Upon Ca2+ binding to the low-affinity, N-terminal domain of CaM, 
dimerization of the CaM-binding regions takes place.  Each N-lobe on the adjacent monomers binds the other’s C-
terminal region, which results in the mechanical opening of the pore helices in the gate region, presenting an 
unparalleled chemo-mechanical activation mechanism. In this complex CaM has a very elongated structure, which 
allows for its interaction with three α-helical segments of the target region [58] (see Fig. (6)). From the Ca2+-loaded 
N-terminal domain Phe12, Phe19, Val35, Met36, Leu39, Phe68, Met71, Met72, the hydrophobic residues lining the 
characteristic pocket, form contacts with the ligand.  The C-lobe, however, is in a Ca2+-free state; small, discrete 
hydrophobic grooves are formed and anchor the residues of the target.  This unconventional binding mode of Ca2+ 
activated K+ channel is created by a CaM binding domain that contains none of the known CaM interaction motifs. 
  
  
Fig. (6).  Complex formation between the gating domain of Ca2+ activated K+ channel and CaM (pdb code: 1g4y , [58]). Ca2+ is 
bound to the N-terminal lobe (located at the top of the monomer at the left side) shown as black spheres. 
 
 Aquaporin-0 (AQP0) is expressed in the eye lens, where its water permeability is regulated by CaM.  Two 
molecules of CaM bind the AQP0 tetramer C-terminal domain in a calcium-dependent manner in a noncanonical 
fashion. The binding mode suggests that CaM may be inhibitory to channel permeability by capping the vestibules of 
two monomers within the AQP0 tetramer. Phosphorylation within AQP0's CaM binding domain inhibits the 
AQP0/CaM interaction, suggesting a temporal regulatory mechanism for complex formation [59].  Mutation 
experiments provide support for these findings demonstrating that phosphorylation determines the calmodulin-
mediated Ca2+ response and water permeability of AQP0 [60]. 
 Even terminal residues of both the target and CaM can induce drastic changes in the complex formed 
between the two.  Myristoylation of terminal residues of a nonapeptide from neuro-specific protein CAP-23/NAP-22 
was shown to play an important role; it determines whether a compact globular complex is formed in the interaction 
with CaM [61].  On the other hand, deletion of the N-terminal leader sequence of CaM alters its interaction with 
myosin light chain kinase, one of the classical examples of “wrap-around” globular complex formation.  If residues 
1-8 are missing from the sequence of CaM, in the complex it will block the catalytic cleft of the kinase, instead of 
exposing it, as expected in case of the auto-inhibitory domain activation mechanism seen in the intact protein-
complex [62]. 
 Based on the bounty of complexation-modes discovered, it seems that for CaM practically everything is 
possible due to its plasticity, which leaves one with the overwhelming question of how is, with such a simple and 
pliable apparatus, specificity and selectivity achieved. 
 
CAM AND CALCIUM 
 
 CaM in itself binds Ca2+ tightly and cooperatively, first to the higher affinity sites of the C-terminal domain 
and then the two sites of the N-terminal domain [63, 64].  However, in the presence of targets, Ca2+ binding becomes 
cooperative for all four sites, relative affinity of the sites changes, might even be reversed, while the absolute affinity 
of the sites might drastically increase in some cases, and diminish in others [58, 65, 66]. On the other hand, in 
contrast to the initial picture of CaM function, a new model evolved considering that target binding can take place in 
the apo, or partially Ca2+-loaded states, too, which in turn profoundly alters the calcium affinity and conformational 
flexibility of CaM [5, 67-75].  Direct evidence supports that Ca2+ binding can be uncoupled from conformational 
change of CaM through the binding of effectors [76, 77]. 
 CaM interacting with Bacillus anthracis anthrax adenyl cyclase exotoxin presents such an example.  The 
binding event takes place in at least two steps.  The association is initiated by the Ca2+-free N-terminal CaM domain, 
followed by the Ca2+-loaded C-terminal domain inserting itself between the catalytic core and the helical domain of 
the toxin [46].  NMR studies have affirmed that in the absence of Ca2+, already a weak interaction between N-CaM 
and the edema factor of the toxin is formed. Binding of Ca2+ to C-CaM renders the interaction stronger while N-
terminal domain exhibits strongly reduced Ca2+ affinity [65].  Crystallization provided an explanation for this.  
Interaction with the helical region of edema factor locks the N terminal domain of CaM into a closed conformation 
independent of its Ca2+-loaded state. Even at elevated Ca2+ levels, when Ca2+ binds to the distorted sites missing one 
or two of the Ca2+ coordinating residues, the transformation to open conformation does not take place: 
conformational switch is uncoupled from Ca2+ binding [50].  These findings were also confirmed by molecular 
dynamics simulations of the complex, where the form with two Ca2+-ions bound to the C-terminal domain of CaM 
resulted in maintaining the active conformation of the edema factor, while the complex formed with 4Ca2+-CaM or 
apo-CaM lead to instability – the unwinding of the central liker of CaM and the collapse of the edema-factor binding 
site [66].  Quite the opposite takes place in case of the Ca2+ activated K+ channel, where the C-terminal lobe of CaM 
is locked into Ca2+-free, partially open state by the association [58]. 
 The presence of apo-CaM is essential for cell survival [67], and it is now certain that some enzymes 
(inducible nitric oxide synthase [68], cyclic nucleotide phosphodiesterase [69, 70], glycogen  phosphorylase [71], 
brush border myosin I [72], and neuronal proteins such as neuromodulins [73], neurogranin [74] and PEP19 [75]) 
actually prefer interacting with this form of CaM [5].  Furthermore, PEP-19, neurogranin and neuromodulin, has 
been noted to enhance dissociation of Ca2+ from calmodulin they seem to represent the machinery of neurons to 
regulate CaM activation in addition to limiting calcium availability [75]. On the other hand, increasing wealth of 
evidence supports that proteins and small molecular ligands that show higher affinity for Ca2+-loaded CaM, can also 
coordinate the Ca2+-free form.  In a number of cases this has functional significance, too; initial binding to apo-CaM 
increases Ca2+-affinity, and a new, tighter complex is formed between Ca2+-bound CaM and the target, which often 
requires the disassembly of the initial association [46, 53, 54]. 
 Different Ca2+-sensing mechanisms can be induced by the accommodation of the CaM lobes within the 
CaM binding sites of target proteins. In complex with voltage gated Ca2+ channels, the C-terminal domain of CaM 
senses large, local changes in Ca2+ concentration while the N-terminal domain reacts to global changes from distant 
sources.  However, if the channel possesses a binding motif called N-terminal spatial Ca2+ transforming element, the 
Ca2+ sensitivity of the N-lobe will be switched to local, too [76, 77]. 
 Accepting that CaM with different levels of Ca2+ saturation shows different target affinity and that target 
binding results in distinct Ca2+ affinity, leads to models that describe the selectivity of CaM, as well.  Construction of 
an allosteric model for Ca2+ binding of CaM that allows for the presence of open conformation in the absence of 
Ca2+, too, was sufficient to describe bidirectional synaptic plasticity mediated by CaM, activating either 
calcium/calmodulin-dependent protein kinase II or protein phosphatase 2B at different calcium concentrations [78].  
The simple and well justified assumption that Ca2+ binding facilitates the transition between the compact, closed and 
the active, open form of CaM Ca2+-binding EF hand motifs, resulted in a model that accounts for the positive co-
operativity of Ca2+ binding to CaM, the activity of its non-saturated forms and the increase of CaM Ca2+ affinity 
upon target binding, through stabilization of the open, high affinity form. Another study, using the structural systems 
biology approach, proposed that beside the diversity of CaM-target interfaces, selectivity of CaM roots from its 
target specific Ca2+-affinity, so the number of Ca2+ ions bound and the target specific cooperative constants [79] will 




CAM AND SMALL MOLECULES 
 
 The extreme variability of binding of protein targets implies that small-molecule ligands may be 
accommodated at a variety of sites on the CaM surface. The modulatory action of this protein is inhibited by 
trifluoperazine (TFP), a small molecule (Fig. (7)A), which competes with target proteins for CaM binding.  TFP 
belongs to typical antipsychotics used basically in the treatment of schizophrenia.  Cook et al. determined the crystal 
structure of the 1:1 complex and found that the central α-helix becomes distorted and the N- and C-terminal domains 
get in close vicinity, like in most complexes of CaM with its targets [13]. The TFP molecule makes extensive, but 
not specific contacts with residues in the C-terminal domain and practically none with the N-terminal domain. The 
structure suggests that substrate binding to the C-terminal domain is sufficient to cause the conformational changes 
in CaM leading to the activation of its targets. It has been thought that the binding of the first TFP molecule to the C-
domain is followed  
 
Fig. (7).  Chemical structure of TFP (A), W7 (B), melatonin (C), serotonin (D), 5-hydroxy-Trp (E), KAR-2 (F), vinblastin (G). 
 
 
by binding of the second one to the N-domain. The crystal structure of the 1:2 CaM-TFP complex proves, however, 
that binding of a TFP molecule to the C-terminal hydrophobic pocket (involving residues Leu105, Ala128, Met124 
and Met144) is followed by the interaction of the second one with an interdomain site [80, 81], where Glu14, Glu114 
and Glu120 participate in the coordination of its positive charge, and Met124 interacts with its phenothiazine moiety. 
It has been shown that the central linker region of the protein is indispensable for simultaneous interactions with two 
TFP molecules. In the 1:4 complex, TFP1, TFP2 and TFP3 are bound to the C-terminal lobe, while TFP4 to the N-
terminal lobe (see Fig. (8)). Both hydrophobic (Val55, Il63, Met71, Met109, Leu116, Met124, Met145) and acidic 
(Glu11, Glu54, Glu114, Glu120) residues of CaM participate in the complexation. The tertiary structure of CaM 
changes from an elongated dumb-bell, with exposed hydrophobic surfaces, to a compact globular form upon TFP 
ligation which hinders its interaction with target proteins [14, 82].  In order to clarify the strength of interaction 
between CaM and TFP in solution, Yamaotsu et al. [83] performed a molecular dynamics simulation of the CaM-
TFP complex in aqueous solution starting from the crystal structure of the 1:4 complex. The obtained solution 
structure is very similar to the structure of the 1:2 complex. The computer simulation showed that the binding ability 
of the secondary binding site of the C-domain is higher than that of the primary binding site of the N-domain. 
 
Fig. (8).  The sequential binding of TFP to CaM.  The 1:1 (A, pdb code: 1ctr, [13]), 1:2 (B, pdb code: 1a29, [81]) and the 1:4 (C, 
pdb code: 1lin, [14]) CaM : TFP complex 
 
 Yet another binding mode of TFP is revealed by its association to melittin bound CaM.  Melittin is a 26 
residue peptide that mimics the targets of CaM and binds to it with nanomolar affinity.  It was a rather surprising 
finding, that instead of displacing melittin from the complex, two molecules of TFP were able to bind to it, forming a 
melittin-TFP2-CaM arrangement.  CD spectroscopic studies of this ternary complex revealed that the two molecules 
of TFP are probably bound to inter-domain sites that are different from those previously detected, stressing again the 
role of the central linker region in fine tuning CaM’s interactions [81]. 
 TFP was also shown to bind Ca2+-free CaM, and cause conformational rearrangement of it to an overall 
ellipsoid shape.  This interaction most likely involves inter- and intra-domain binding sites, and still another mode of 
TFP accommodation by CaM [82].  The non-specific nature of TFP ligation to CaM was also underlined by 
molecular dynamics simulation of the CaM : 2TFP complex, where it was shown, that the surface close ionic 
attraction between Glu residues of CaM and the positive charge of the piperazine ring of each TFP molecule looses 
its significance when solvation is introduced and the surface close acidic residues can interact with water instead of 
the delocalized charge of TFP.  This then leaves TFP greater conformational freedom within the hydrophobic interior 
of the complex [84]. 
 The solution structure of the N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W7)-CaM complex 
(see W7 in Fig. (7)B) has been determined by multidimensional NMR spectroscopy [85, 86]. The structure contains 
two molecules of the inhibitor, each binding competitively to the N- and C-terminal domain of the protein. It is quite 
interesting to see that both the elongated, dumbbell shape and the compact, globular form appears among the 
solutions, with both the N- and the C-terminal hydrophobic patches are occupied.  The two bound molecules interact 
with independent binding sites, no interdomain site is formed, and the terminal lobes freely rotate with respect to 
one-another [85] (see Fig. (9)).  Small angle X-ray scattering results argue in favor of the compact globular shape 
[86], indicating again, the great plasticity of the CaM backbone.  According to the NMR structure, the 
chloronaphthalene ring interacts with methionine side chains and other aliphatic or aromatic side chains in the deep 
hydrophobic pockets of the terminal lobes of CaM. The orientation of the W7 naphthalene ring in the N-terminal 
pocket is rotated to a certain extent with respect to that in the C-terminal pocket, however the residues forming the 
binding sites are quite similar, Phe19/Phe92, Leu32/Leu105, Met51/Ile125, Ile52/Ala128, Ile63/Val136, 
Phe68/Phe141, Met72/Met144-Met145 in the N-terminal/C-terminal domains, respectively.  The role of the four Phe 
residues seems to be the shielding of the chloronaphthalene ring from the polar backbone atoms of each lobe. 
Although the W7 ring orientation differs significantly from that of the Trp800 indole ring of chicken smooth muscle 
myosin light chain kinase bound to the same hydrophobic cleft of the C-terminal pocket and that of the 
phenothiazine ring of trifluoperazine bound to either the N- or the C-terminal pocket, the results demonstrate that the 
hydrophobic pockets of CaM can accommodate a variety of bulky aromatic rings. 
 Melatonin (N-acetyl-5-methoxytryptamine; Fig. (7)C), another small-molecular ligand of CaM, which is an 
even closer mimic of Trp than W7, provides a further elucidation of this question. Melatonin is an endogenous CaM 
antagonist; it is used as a chemotherapeutic agent.  Melatonin is thought to modulate the calcium/CaM signaling 
pathway either by changing intracellular Ca2+ concentration via activation of its G-protein-coupled membrane 
receptors, or through a direct interaction with CaM. Although contradicting conclusions were reached as to its 
inhibition of CaM dependent protein kinase II [87, 88], it has been demonstrated that complex formation between 
CaM and melatonin prevents the activation of neuronal nitric oxide synthase [89], and plays an important role in 
mediating the growth-inhibitory effect in cancer cells [90].  Binding conformation of melatonin to CaM was studied 
by fluorescence and NMR spectroscopic experiments and by molecular dynamics simulations [2]. Both experimental 
and MD results indicate that the calcium-dependent interaction of melatonin with CaM is significant but weak.  
Since melatonin is quite similar to the Trp residue, it might not be so surprising that its indole ring binds to the Trp 
accommodating hydrophobic cleft, as shown by the molecular dynamics simulation.  The extra O-methyl substituent 
of its indole ring does not disrupt the interaction; it points to the bottom of the pocket while the ethylamide side chain 
is located in the entrance.  The molecule binds mainly via its indole ring, which is surrounded by the methionines of 
the hydrophobic pocket of CaM, maximizing the interaction. Analysis of the changes in potential energy during the 
trajectory suggests that electrostatics plays a major role in determining melatonin position and conformation. Having 
a hydroxyl group in place of the O-methyl of melatonin, as in serotonin (see Fig. (7)D), further weakens the 
interaction, and in the case of 5-hydroxy-Trp (see Fig. (7)E) completely abolishes it, demonstrating the significance 
of hydrophobic forces in the interaction [88]. 
 3`-(β-chloroethyl)-2`,4`-dioxo-3,5`-spiro-oxazolidino-4-deacetoxyvinblastine (KAR-2; Fig. (7)F), a 
semisynthetic bisindole alkaloid is a potent anti-microtubular agent that arrests mitosis in cancer cells without 
significant toxic side effects. It has been demonstrated that KAR-2 also binds to CaM, somewhat neutralizing the 
antagonistic effects of TFP. Crystal structure determination of KAR-2 was partially triggered by the curious 
observations that this drug molecule is able to bind to the CaM-TFP complex without displacing TFP from it [80], 
and that, in spite of the fact that it does interact with CaM, does not affect the protein’s action on 1-
phosphofructokinase [91] and is unable, at any concentration, to decrease CaM dependent phosphodiesterase activity 
below 50% [81].  Accordingly, the crystal structure of the complex revealed a novel binding mode for this drug (see 
Fig. (9)) while nuclear magnetic resonance spectroscopy indicated that solution structure of the complex is also 
consistent with the crystal structure [18]. 
 
Fig. (9).  The structure of the CaM-KAR-2 complex (pdb code:1xa5, [18]). 
 
 The structure provided immediate explanation to this unique behavior.  Ca2+ loaded CaM binds KAR-2 in a 
compact, “wrap-around” conformation similar to that seen in its TFP or peptide complexes, however, the KAR-2 
molecule is situated in an inter-domain position between the N- and C-terminal lobes, leaving the hydrophobic, intra-
domain clefts unoccupied. It only makes close contacts with Leu18, Leu39, Phe68 and Ile85, while its polarizable 
chlorine atom is loosely coordinated by Met109 and Glu114. Therefore, binding of KAR-2 pre-assembles the target 
binding, globular conformation of CaM, without competing for the most specific, hydrophobic binding sites. 
Superimposition of the structures of the CaM-KAR-2 and CaM-TFP 1:1 complexes demonstrates that KAR-2 and 
the C-terminal bound TFP are accommodated in distinct sites. A surprising feature of the interface between KAR-2 
and CaM is that the hydrophobic pockets are distorted by the drug binding. This conformational change induces a 
limited inhibitory effect on CaM mediated events [18]. 
 Vinblastine (Figure 7G), the mother compound of KAR-2, in contrast, is a competitive inhibitor, its 
interaction with CaM is completely abolished by the presence of TFP.  It is, however, able to bind in the presence of 
KAR-2, although the two drugs mutually weaken each-other’s binding, which suggests that they interact with 
distinct, but partially overlapping sites.  This is made significant by the fact that the structures of KAR-2 and 
vinblastine are very similar, in fact, identical in the catharantine part, with a difference of only a few atoms of the 
vindoline moiety, where KAR-2 carries a substituted oxazolidino ring, closed across the two C-3 substituents. Data 
suggest that, while vinblastine, devoid of this five-membered ring, is able to fit in the hydrophobic groove of the C-
terminal lobe of CaM, KAR-2 is no longer able, due to the presence of it [81]. 
 Binding with a further antagonist N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide (J8; Fig. (10)A) was  
 
 
Fig. (10).  Chemical structure of J8 (A), AAA (B), an arylamide derivative (C), HBCP (D).  
 
investigated by NMR spectroscopy by Craven et al. [15]. It has been shown that the primary interaction between J8 
and CaM is between the naphthalene ring of the former and the hydrophobic pockets of the protein (Phe92 and 
Phe141 implicated in the interaction with the C-terminal region) resulting in a 2:1 (J8: CaM) complex, similar to the 
binding of the hydrophobic side-chain residues of calmodulin target peptides. It was found that the aliphatic amino 
group of the ligand is highly mobile, and it forms no or only weak interaction with the protein. 
 A further type of CaM antagonists is N-(3,3-diphenylpropyl)-N`-[1-R-(3,4-bis-butoxyphenyl)ethyl]-
propylene-diamine (AAA; Fig. (10)B), which also forms a 1:2 complex with the protein, binding both to the N- and 
C-terminal pockets [17] in a very similar orientation (see Fig. (4)). The binding of AAA leads to domain closure 
similarly to the case of the 4TFP-CaM complex. The two bound AAA molecules also interact with each other by 
hydrophobic forces.  This might be the reason for the tightness of binding, creating a favorable entropy term for the 
association, as suggested by the authors.  The binding affinity and antagonistic potency of the molecule is in the 
nanomolar range. Binding of the AAA molecule in the C-terminal domain involves all three TFP-binding sites as 
located by X-ray crystallography, however, in the N-terminal domain only one TFP binding site is involved, which 
was observed in the 1:4 complex [14]. This supports the hypothesis that two additional binding sites, approximately 
equivalent with the inter-domain ones, may be present in the complex. The structure of the complex was 
independently determined from two crystals belonging to different space groups.  It is interesting to note, that while 
the accommodation of the diphenylpropyl moiety of AAA was quite similar in both cases, due to the differences in 
the tertiary structure of CaM, the 3,4-bis-butoxyphenyl coordination was achieved in a variety of different modes.  
The differences in the backbone structure of CaM determined from the two different crystals is the degree of its 
domain closure, which also shows how subtle changes are sufficient (in this case, a change in crystal packing forces) 
to create markedly different arrangements of this highly flexible molecule. 
 Using a thioether substituted arylamide scaffold, highly specific CaM inhibitors were designed that also 
showed nanomolar inhibitory effect.  The most successful molecule is capped with D-Phe group at each end to 
withstand proteolysis, and is equipped with flexible amine sidechains to facilitate interaction with the acidic residues 
of CaM (see Fig. (10)C).  Arylamide derivatives mimic membrane binding helical peptides [92] and are thought to 
bind to CaM in a similar way to that of smooth muscle myosin light chain kinase based on 2D (1H, 15N)-HSQC NMR 
spectra [93].  The compound, HBCP (Fig. (10)D) was shown to be a potent Ca2+/CaM antagonist with anti-
proliferate activity against colorectal cancer cells [94].  It was shown to inhibit cell proliferation with an IC50 value of 
3µM  based on which the authors suggest its use as a probe of CaM functions in cell proliferation signaling networks 
as well as a potential lead compound targeting CaM. 
 
CAM AND LIGAND DESIGN 
 
Although the protein-CaM interactions are diverse and activation mechanisms vary, the conformation of N- 
and C-terminal lobes of CaM seem to depend primarily on Ca2+ saturation, while the conformational flexibility of the 
different Ca2+-loaded forms is focused on their central linker. The hydrophobic crevices can accommodate various, 
quite dissimilar amino acid residues and small molecules. The plasticity of the hydrophobic pocket ensures binding 
and adapting to different molecular fragments. Most of the small molecules bound to the hydrophobic patches 
possess an inhibitory role on CaM mediated processes. However, it seems that tight and specific binding with these 
surfaces in not so easily achieved. 
CaM is a highly acidic protein, therefore small molecule ligands possessing both hydrophobic and positively 
polarized moieties would be expected to coordinate to it with ease.  However, antagonists with net positive charge 
(trifluoroperazin for example) or easily polarized heteroatoms (like W7 or KAR-2) form only few, non-specific ionic 
interactions with it.  This might be because the negatively charged amino acids of CaM tend to be surrounded by 
bulky hydrophobic residues which shield them from straightforward electrostatic contacts – for example, along 
Glu11 we find Phe12, by Glu14, Ala15 and Leu18 and the through-space neighbor of Glu120 is Leu116. That the 
Glu and Asp residues of CaM are indeed difficult to reach is reflected by the structure of the peptide complexes of 
the protein.  In 13 selected structures representing a wide array of different binding arrangements [46, 48, 49, 95-
104], 53 H-bond contacts (with heteroatom distance within 3.5 Å) between negatively charged amino acids of CaM 
and its complexed peptides were identified.  In 85% of the cases, the interacting partner was a Lys or an Arg residue, 
and in only 8 cases did other possible proton donors, such as Thr, His, Ser, Asn and Gln take part in the interactions. 
In the 13 complexes analyzed, in only one case was the carboxylate group of a CaM residue coordinated by 
backbone amide nitrogen of the target peptide [84]. This demonstrates that the negative charge centers of CaM prefer 
interacting with such molecular segments where an isolated positive charge is located at the end of a long, flexible 
aliphatic chain.  Successful candidates should therefore contain hydrophobic anchors and positively polarizable 
groups at the end of a long tether – such as the D-Phe substituted arylamide molecule, which did show nanomolar 
inhibitory effect [93] (see Fig. (10)C). 
However, strong binding does not insure selectivity in case of CaM.  A significant overlap in interacting 
residues can be seen in spite of the varying degree of domain closure upon complexation, due to the fact that the 
terminal lobes function as independent sites as well.  Glu11 is the gatekeeper, it comes into contact with practically 
anything ligated, although the surface-close electrostatic interactions it forms are probably more significant in the 
crystal structures than in the physiological, solvated states [83].  Glu14, Phe19, Met71, Met72 of the N-terminal and 
Glu114, Met124, Met144 of the C-terminal domains are commonly appearing partners of different ligands, while 
Glu84 and Glu87 of the central linker form several H-bond interactions too. However, specificity can also be found.  
For example, in case of the edema factor of Bacillus anthracis anthrax adenyl cyclase, Ser38 and Arg90 of CaM, 
which are both outside the canonical set, form strong H-bonds with a Ser and an Asp residue of the target, 
respectively [46, 50].  Disrupting these interactions would possibly destabilize the complex, while leaving the most 
commonly used binding spots free for coordination of other targets.  KAR-2 is a nice example of selectivity achieved 
in this fashion. With this potent anti-microtubular agent bound to the interdomain site of the globular form, CaM 
retains its 1-phosphofructokinase and phosphodiesterase activating capacity [81, 91].  On the other hand, “classical” 
CaM antagonists, binding to the hydrophobic patches of the terminal lobes, such as TFP and W7, do not inhibit the 
activity of intermediate Ca2+ activated K+ channels [105], in spite of the fact, that Ca2+-CaM-induced conformational 
changes are necessary for the channel opening [106, 107], therefore CaM participation in the activation process is 
un-debatable.  Thus, specific pharmacophore design should not be impossible. 
Computer-aided studies of CaM and its interaction with ligands look back on a long history, however, 
taking into consideration the significance of CaM, such studies are surprisingly few.  Prior to the determination of 
the crystal structure of CaM, a model of it was built based on the structure of troponin-C. Trifluoperazine binding 
was studied, predicting its ligation to an interdomain site of the elongated protein [108].  In another pioneering study, 
following the crystal structure determination of the Ca2+-loaded, open form of CaM [29], tamoxifen binding was 
studied and optimized.  Ligand binding to the independent C-terminal hydrophobic cleft was supposed, disregarding 
the possibilities of the bending of the central linker region or the association of the terminal lobes.  Optimization of 
the molecular structure took place within this framework by energy-minimization calculations, which, combined 
with functional studies lead to the discovery of compounds showing micromolar IC50 values in the antagonism of 
calmodulin-dependent activity of cAMP phosphodiesterase.  Also, a correlation was found between CaM antagonism 
and cytotoxicity against MCF-7 breast tumor cells in vitro [109].  
Molecular dynamics studies have successfully complemented structural analysis and aided interpretation of 
the results in a number of cases [2, 32, 33, 45, 52, 66, 83, 84, 110]. 
QSAR methodology was also applied to CaM.  Liu and coworkers classified 24 calmodulin inhibitors into 
three groups (groups I, II and III), Using discriminant analysis they developed discriminant functions that 
distinguished between the groups in terms of positive potential surface area on the side chain, as well as the total and 
neutral surface areas on the ring in the inhibitor molecules. The results of their QSAR analysis showed that 
hydrophobicity was important for the ring moiety but not for the side chain, which should contain the nitrogen atom 
far from the ring moiety [111].  In another study QSAR methodology was applied to the characterization of 
diphenylalkylamines implicated in the antagonistic effect of CaM toward CaM-stimulated phosphodiesterase.  Chain 
length, the presence or absence of the methyl group vicinal to the nitrogen atom, the methylation of the nitrogen 
atom as well as the presence of the oxygen as heteroatom in combination with benzhydryl substitution have been 
indicated as the most important molecular descriptors [112] 
Due to the diverse biological role of CaM, its antagonists showed significant promise for the pharma 
industry, initiating drug design research in the mid 90s. Several companies including Novartis, Akzo-Nobel, Takeda, 
Mitsubishi Tanabe, Banyu, Daiichi Sankyo and Kaken filed more than 30 patent application claiming CaM 
antagonists for therapeutic use. Most of the indications belong to cardiovascular and neurological disorders including 
hypertension, angina pectoris, stroke and other cerebrovascular diseases. Although there were several compounds in 
preclinical development, only two of these reached the clinic. Zaldaride (see Fig. (11)A) was originally discovered 
by Gebro Pharma and Novartis [113] and was licensed to Kyowa Hakko that investigated the compound in a phase 3 
antidiarrheal trial in Japan. Unfortunately this late phase trial was reported to be discontinued in 2000 [114]. 
 
 
Fig. (11).  CaM antagonists in clinical and preclinical development  
The other clinically investigated CaM antagonist is DY-9760 (see Fig. (11)B), a compound discovered by 
Daiichi Sankyo [115].  DY-9760 reached phase 1 in ischemic stroke indication in Japan and Europe, however these 
studies were discontinued in 2000 and 2002, respectively. No reasoning has been reported by the company [114]. 
Compounds, which reached the preclinical development represent five different chemotypes. Takeda 
reported imidazopyridines as CaM antagonists (see Fig. (11)C) [116].  Mitsubishi Tanabe identified dually acting 
tetrahydro-benzothiepine type CaM inhibitors (see Fig. (11)D) with calcium channel blocking activity for the 
treatment of hypertension and angina pectoris [117].  The company also described the pure CaM inhibitor TI-233 
[114] as a development candidate for coagulation disorders therapy particularly for the treatment of thrombosis (see 
Fig. (11)E), however, no active development was reported. 
Akzo-Nobel filed one patent application [118] claiming bis-phenyl-methylthio-ethyl-phenylethylamines as 
calmodulin antagonists against angina pectoris (see Fig. (11)F). Banyu described W-7 as potent and selective CaM 
antagonist (see Fig. (7)B) in two patent applications [119]. The compound is in preclinical development; however, no 
further progress has been reported. 
In conclusion, the development data available for calmodulin antagonists in different indications suggest 
that the complex physiological role of this enzyme make drug development difficult. Although the structure of the 
enzyme has been available for more than 20 years and a number of potent and selective calmodulin antagonists have 
been identified up to now no pharmacotherapy related to this single mechanism was reported. We think that 
calmodulin antagonism as monotherapy might be less suitable for medical intervention. In combination with other 
mechanism or more importantly targeting specific CaM mediated pathophysiological processes might convert the 
already accumulated biochemical and structural biology knowledge to therapeutic value. 
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